FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Taps Murphy to Head Generic Drugs Office

[ Price : $8.95]

FDA names CDER Office of Generic Drugs safety and clinical evaluation acting director Iilun Murphy as the next OGD director, repla...

FDA Approves Production at BMS CAR T Facility

[ Price : $8.95]

FDA greenlights commercial production of CAR T cell therapy at a new Bristol Myers Squibb manufacturing site in Devens, MA.

Panel Backs RSV Monoclonal Antibody

[ Price : $8.95]

FDAs Antimicrobial Drugs Advisory Committee votes unanimously that AstraZeneca and Sanofis nirsevimab has a favorable benefit-risk...

Create One PPI Guidance for all Products: Novartis

[ Price : $8.95]

Novartis urges FDA to broaden its proposal on patient preference information beyond medical devices.

Assessing GDUFA User Fees Guidance

[ Price : $8.95]

FDA publishes a guidance with specifics about changes to user fees imposed under the GDUFA 3 reauthorization in 2022.

FDA OKs Novaliq Dry Eye Drug

[ Price : $8.95]

FDA approves a Novaliq NDA for Vevye (cyclosporine ophthalmic solution) 0.1% for treating the signs and symptoms of dry eye diseas...

FDA Ups Pediatric Exclusivity Requirements: Attorneys

[ Price : $8.95]

Two SheppardMullin attorneys describe how two recent FDA guidances on pediatric drug development will tighten eligibility for pedi...

FibroGens Pamrevlumab Fails Phase 3

[ Price : $8.95]

FibroGen says its pamrevlumab failed to meet the primary endpoint in treating Duchenne Muscular Dystrophy in a Phase 3 trial.

AdvaMed Recommendations for Patient Preference

[ Price : $8.95]

AdvaMed says it agrees with FDA on questions to be added to a guidance on the submission of patient preference information, and al...

Teleflex Pacing Guidewire Cleared

[ Price : $8.95]

FDA clears a Teleflex 510(k) for its Wattson Temporary Pacing Guidewire a bipolar temporary device designed specifically for use ...